Skip to content

Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software

Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04495829
Enrollment
70
Registered
2020-08-03
Start date
2020-07-24
Completion date
2021-04-21
Last updated
2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors

Brief summary

The objective of the current study is to prospectively evaluate 3-month clinical outcomes from LASIK performed using the Phorcides surgical planning software with Contoura topography-guided ablation in both eyes of subjects with myopia and myopic astigmatism seeking refractive surgery for distance correction.

Detailed description

The objective of the current study is to prospectively evaluate 3-month clinical outcomes from LASIK performed using the Phorcides surgical planning software with Contoura topography-guided ablation in both eyes of subjects with myopia and myopic astigmatism seeking refractive surgery for distance correction. Data will be compared to published results for wavefront optimized LASIK and LASIK performed with Contoura using other refractive algorithms. The hypothesis is that use of the Phorcides planning software will result in a higher percentage of eyes with residual refractive cylinder ≤ 0.25D than will be achieved with wavefront-optimized (WFO) LASIK. It is also expected that unaided postoperative visual acuity and visual symptoms will be improved.

Interventions

DEVICEPhorcides Analytical Engine

Surgery planning using the Phorcides analytical engine.

Sponsors

Science in Vision
CollaboratorOTHER
Alcon Research
CollaboratorINDUSTRY
American Corneal Consultants
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Candidate for Contoura excimer laser vision correction * Gender: males and females. * Age: 20 or older * Willing and able to provide written informed consent for participation in the study. * Willing and able to comply with scheduled visits and other study procedures. * Good ocular health, with no pathology that compromises visual acuity (other than refractive error) * Corrected preoperative visual acuity of 20/20 (0.0 logMAR) or better in the eye being treated * Meet Contoura eligibility requirements (approved range): up to -8.00 D sphere, up to -3.00 D cylinder, and a spherical equivalent no greater than -9.00 D * Desire good vision at distance in both eyes

Exclusion criteria

* Corneal pathology (e.g. opacities, epithelial basement membrane dystrophy, Fuchs' dystrophy, etc.) * Previous corneal surgery (e.g., radial keratotomy, corneal refractive surgery or corneal transplant, DSAEK, DMEK, lamellar keratoplasty) * Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy) * Desire for good uncorrected near vision in one or both eyes * Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial * Unsuitability for the trial, in the opinion of the investigator, for any reason * Pregnancy or desire to become pregnant during the trial * Intraoperative complications.

Design outcomes

Primary

MeasureTime frameDescription
Residual Refractive Cylinder3 months postopResidual refractive cylinder in diopters

Secondary

MeasureTime frameDescription
Uncorrected Distance Visual Acuity3 months postopUncorrected visual acuity at distance (4-6m)
Residual Refractive Sphere3 months postopResidual refractive spherical equivalent in diopters
Satisfaction and Vision3 months postopA questionnaire related to visual quality and satisfaction after surgery

Countries

United States

Participant flow

Participants by arm

ArmCount
Phorcides
Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software. Phorcides Analytical Engine: Surgery planning using the Phorcides analytical engine.
70
Phorcides
Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software. Phorcides Analytical Engine: Surgery planning using the Phorcides analytical engine.
140
Total210

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyInclusion criterion not met3
Overall StudyLost to Follow-up2

Baseline characteristics

CharacteristicPhorcides
Age, Continuous31 years
STANDARD_DEVIATION 5.4
Corrected distance VA-.04 logMAR
STANDARD_DEVIATION 0.04
MRSE-3.6 diopters
STANDARD_DEVIATION 1.79
Refractive cylinder0.54 diopters
STANDARD_DEVIATION 0.49
Region of Enrollment
United States
70 participants
Sex: Female, Male
Female
38 Participants
Sex: Female, Male
Male
27 Participants
Uncorrected distance VA.95 logMAR (log of min angle of resolution
STANDARD_DEVIATION 0.33

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 70
other
Total, other adverse events
1 / 70
serious
Total, serious adverse events
0 / 70

Outcome results

Primary

Residual Refractive Cylinder

Residual refractive cylinder in diopters

Time frame: 3 months postop

ArmMeasureValue (MEAN)Dispersion
PhorcidesResidual Refractive Cylinder0.04 dioptersStandard Deviation 0.09
Secondary

Residual Refractive Sphere

Residual refractive spherical equivalent in diopters

Time frame: 3 months postop

ArmMeasureValue (MEAN)Dispersion
PhorcidesResidual Refractive Sphere0.08 dioptersStandard Deviation 0.2
Secondary

Satisfaction and Vision

A questionnaire related to visual quality and satisfaction after surgery

Time frame: 3 months postop

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
PhorcidesSatisfaction and VisionDouble visionNone to moderate65 Participants
PhorcidesSatisfaction and VisionDouble visionMarked to severe0 Participants
PhorcidesSatisfaction and VisionTrouble driving at nightNone to moderate65 Participants
PhorcidesSatisfaction and VisionTrouble driving at nightMarked to severe0 Participants
PhorcidesSatisfaction and VisionTrouble readingNone to moderate65 Participants
PhorcidesSatisfaction and VisionTrouble readingMarked to severe0 Participants
PhorcidesSatisfaction and VisionDrynessNone to moderate63 Participants
PhorcidesSatisfaction and VisionDrynessMarked to severe2 Participants
PhorcidesSatisfaction and VisionForeign body sensationNone to moderate65 Participants
PhorcidesSatisfaction and VisionForeign body sensationMarked to severe0 Participants
PhorcidesSatisfaction and VisionFluctuation in visionNone to moderate65 Participants
PhorcidesSatisfaction and VisionFluctuation in visionMarked to severe0 Participants
PhorcidesSatisfaction and VisionGlareNone to moderate65 Participants
PhorcidesSatisfaction and VisionGlareMarked to severe0 Participants
PhorcidesSatisfaction and VisionHalosNone to moderate65 Participants
PhorcidesSatisfaction and VisionHalosMarked to severe0 Participants
PhorcidesSatisfaction and VisionLight sensitivityNone to moderate63 Participants
PhorcidesSatisfaction and VisionLight sensitivityMarked to severe2 Participants
PhorcidesSatisfaction and VisionPainNone to moderate65 Participants
PhorcidesSatisfaction and VisionPainMarked to severe0 Participants
PhorcidesSatisfaction and VisionStarburstsNone to moderate65 Participants
PhorcidesSatisfaction and VisionStarburstsMarked to severe0 Participants
Secondary

Uncorrected Distance Visual Acuity

Uncorrected visual acuity at distance (4-6m)

Time frame: 3 months postop

ArmMeasureValue (MEAN)Dispersion
PhorcidesUncorrected Distance Visual Acuity-.11 logMARStandard Deviation 0.06

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026